These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 6437038

  • 1. Bone disease in long-term hemodialysis patients with low dialysate aluminium.
    Grekas DM, Ellis HA, Ward MK, Martin AM, Parkinson I, Kerr DN.
    Uremia Invest; 1984; 8(1):9-15. PubMed ID: 6437038
    [Abstract] [Full Text] [Related]

  • 2. Bone aluminum and histomorphometric features of renal osteodystrophy.
    Hodsman AB, Sherrard DJ, Alfrey AC, Ott S, Brickman AS, Miller NL, Maloney NA, Coburn JW.
    J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841
    [Abstract] [Full Text] [Related]

  • 3. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption.
    Heaf JG, Pødenphant J, Andersen JR.
    Nephron; 1986 Mar; 42(3):210-6. PubMed ID: 3945361
    [Abstract] [Full Text] [Related]

  • 4. Evidence of increased parathyroid activity on discontinuation of high-aluminum dialysate in patients undergoing hemodialysis.
    O'Hare JA, Murnaghan DJ.
    Am J Med; 1984 Aug; 77(2):229-32. PubMed ID: 6431809
    [Abstract] [Full Text] [Related]

  • 5. Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid.
    Carmichael KA, Fallon MD, Dalinka M, Kaplan FS, Axel L, Haddad JG.
    Am J Med; 1984 Jun; 76(6):1137-43. PubMed ID: 6328994
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients.
    Heaf JG, Nielsen LP, Mogensen NB.
    Nephron; 1983 Jun; 35(2):103-7. PubMed ID: 6621754
    [Abstract] [Full Text] [Related]

  • 10. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P, Boudailliez B, Hocine C, Belbrik S, Renaud H, Westeel PF, Solal MC, Fournier A.
    Nephrol Dial Transplant; 1989 Jun; 4(12):1045-53. PubMed ID: 2517325
    [Abstract] [Full Text] [Related]

  • 11. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
    Chazan JA, Libbey NP, London MR, Pono L, Abuelo JG.
    Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
    [Abstract] [Full Text] [Related]

  • 12. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure.
    Andress DL, Ott SM, Maloney NA, Sherrard DJ.
    N Engl J Med; 1985 Feb 21; 312(8):468-73. PubMed ID: 3969109
    [Abstract] [Full Text] [Related]

  • 13. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness.
    Pierides AM, Edwards WG, Cullum UX, McCall JT, Ellis HA.
    Kidney Int; 1980 Jul 21; 18(1):115-24. PubMed ID: 7218657
    [Abstract] [Full Text] [Related]

  • 14. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis.
    Ellis HA, Pierides AM, Feest TG, Ward MK, Kerr DN.
    Clin Endocrinol (Oxf); 1977 Dec 21; 7 Suppl():31s-38s. PubMed ID: 606422
    [Abstract] [Full Text] [Related]

  • 15. Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome.
    Norris KC, Crooks PW, Nebeker HG, Hercz G, Milliner DS, Gerszi K, Slatopolsky E, Andress DL, Sherrard DJ, Coburn JW.
    Am J Kidney Dis; 1985 Nov 21; 6(5):342-7. PubMed ID: 4061454
    [No Abstract] [Full Text] [Related]

  • 16. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB, Hood SA, Brown P, Cordy PE.
    J Lab Clin Med; 1985 Dec 21; 106(6):674-81. PubMed ID: 4067379
    [Abstract] [Full Text] [Related]

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 21; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 18. Does strict phosphorus control precipitate renal osteomalacia?
    Delmez JA, Fallon MD, Harter HR, Hruska KA, Slatopolsky E, Teitelbaum SL.
    J Clin Endocrinol Metab; 1986 Apr 21; 62(4):747-52. PubMed ID: 3949954
    [Abstract] [Full Text] [Related]

  • 19. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S, Oprisiu R, Benamar L, Said S, Tataru Albu A, Arsenescu I, el Esper N, Morinière P, Fournier A.
    Nephrologie; 2000 Apr 21; 21(8):413-24. PubMed ID: 11213385
    [Abstract] [Full Text] [Related]

  • 20. [The role of aluminum in the development of osteomalacia in patients on chronic hemodialysis].
    Adamiec R, Uzar J.
    Pol Arch Med Wewn; 1988 Jan 21; 79(1):3-12. PubMed ID: 3275167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.